Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MGI to split shares 2-for-1

MOGN's board approved a 2-for-1 split of

Read the full 71 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE